Q-omics provides the consensus-scored PSMD7 profile across patient tissues and cancer cell-line models. PSMD7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PSMD7 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PSMD7 protein abundance shows 37,803 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, and LUAD as cancer lineages where PSMD7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMD7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMD7 survival associations across molecular data types. PSMD7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMD7 RNA expression–survival associations across cancer types. High PSMD7 expression shows unfavorable associations in HNSC, ACC, BLCA, BRCA, LIHC and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PSMD7 RNA expression.
This table summarizes PSMD7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMD7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMD7 shows higher tumor expression in HNSC, COAD, KIRP, KIRC, LIHC and LUAD. The HNSC box plot shows higher PSMD7 RNA expression in tumor versus normal tissue (log2 FC = +0.990, t-test p < 0.001).
This table shows molecular features associated with PSMD7 in patient tissues and cancer cell lines. In patient samples, PSMD7 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMD7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
